Circulating CD15
            <sup>+</sup>
            LOX‐1
            <sup>+</sup>
            PMN‐MDSCs are a potential biomarker for the early diagnosis of non‐small‐cell lung cancer

Tian, Xinyu; Wang, Ting; Zheng, Qisi; Tao, Yue; Dai, Lei; Shen, Han

doi:10.1111/ijcp.14317

Cited by 5 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LOX-1+ CD15+ PMN-MDSCs proportion enhances in the case of NSCLC and recurrence. All these findings were detected using flow cytometry in the peripheral blood of patients with NSCLC and health controls [91].…”

Section: Experimental Medicine Involving Cd15mentioning

confidence: 96%

CD15 and CD15s in The Anticancer Therapy

Szlasa¹,

Wilk²,

Knecht-Gurwin³

et al. 2022

Preprint

View full text Add to dashboard Cite

CD15 (Lewis X/Lex) is a fucosyl (3-fucosly-N-acetyl-lactosamine) moiety found on membrane proteins of various cancer cells. These include renal cancer, prostate and bladder cancers, acute leukemias, hepatocellular carcinoma, breast cancer and melanoma. The antigen plays an espe-cially significant role in renal cell carcinoma. Its high expression serves as a good prognostic marker for patients and high hopes are related to its use in the immunotherapy of the tumor. The biological role of CD15 is the interaction with E-, L- and P-selectins (adhesion molecules) and al-lowing for the adhesion with the endothelial cells. In this way, cancer cells start to interact with the endothelium of blood vessels and consequently move out from the blood flow to the sur-rounding tissues. The blockage of antigen’s function results in reduced metastatic potential. Moreover, the molecule may be a therapeutic target against cancer in monoclonal antibod-ies-based therapies. CD15s is a sialyl derivative of CD15, that possess its own unique characteris-tics. Unlike high expression of CD15, which is a prognostic factor in Hodgkin lymphoma, CD15s relate to poor prognosis for the patients. Due to the high abundance in cancer cells, CD15 is con-sidered as a marker of Cancer Stem Cells. This review presents a comprehensive description of the role of CD15 and CD15s in cancer development and metastasis and overviews the clinical appli-cations of the anti-CD15 therapy.

show abstract

Section: Experimental Medicine Involving Cd15mentioning

confidence: 96%

CD15 and CD15s in The Anticancer Therapy

Szlasa¹,

Wilk²,

Knecht-Gurwin³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The circulating M‐MDSC subset is significantly increased compared to that in healthy donors (Heuvers et al., 2013; Huang et al., 2013; Yamauchi et al., 2018) and is associated with poor overall survival (Bronte et al., 2022; Zahran et al., 2021). Likewise, there is a higher percentage of polymorphonuclear MDSCs in the peripheral blood of patients with NSCLC compared to healthy donors, along with higher levels of arginase 1 (Barrera et al., 2018; Heuvers et al., 2013; Tian et al., 2021).…”

Section: Commentarymentioning

confidence: 99%

Functional Flow Cytometry to Predict PD‐L1 Conformational Changes

Salvia,

Rico,

Ward

et al. 2023

Current Protocols

View full text Add to dashboard Cite

The programmed cell death protein 1/programmed cell death protein ligand 1 (PD‐1/PD‐L1) axis is one of the most widely recognized targets for cancer immunotherapy. Importantly, PD‐L1 conformational changes can hinder target binding when living cells are used. Antibody affinity, equilibrium binding, association and dissociation rates, and other affinity‐related constants are fundamental to ensure target saturation. Here, PD‐L1 changes in conformation and their potential impact on PD‐L1 function and mutation are explored. Specifically, we present detailed flow cytometry procedures to analyze PD‐L1 reactivity in myeloid‐derived suppressor cells (MDSCs). This approach can also be used to study the contribution of protein conformational changes in living cells. © 2023 Wiley Periodicals LLC.Basic Protocol 1: Sample preparation for PD‐L1+ myeloid‐derived suppressor cells detection by flow cytometryBasic Protocol 2: Protocol preparation, sample acquisition, and gating strategy for flow cytometric screening of PD‐L1+ myeloid‐derived suppressor cells in patients with lung cancerSupport Protocol 1: Bioinformatic tools for the analysis of flow cytometric data

show abstract

“…LOX-1 + CD15 + PMN-MDSC proportions are enhanced in cases of NSCLC and recurrence. All these findings were made through flow cytometric analysis of the peripheral blood of patients with NSCLC and health controls [35].…”

Section: Role Of Cd15 and Cd15s In Neoplasmsmentioning

confidence: 99%

Prognostic and Therapeutic Role of CD15 and CD15s in Cancer

Szlasa

Wilk

Knecht-Gurwin

et al. 2022

Cancers

View full text Add to dashboard Cite

CD15 (Lewis X/Lex) is a fucosyl (3-fucosly-N-acetyl-lactosamine) moiety found on membrane proteins of various cancer cells. These cancers include renal cancer, prostate and bladder cancers, acute leukaemias, hepatocellular carcinoma, breast cancer and melanoma. The biological role of CD15 is interaction with E-, L- and P-selectins (adhesion molecules), allowing for adhesion with endothelial cells. In this way, cancer cells start to interact with the endothelia of blood vessels and consequently move out from the blood flow to the surrounding tissues. Blockage of the antigen’s function results in reduced metastatic potential. Moreover, the molecule may be a therapeutic target against cancer in monoclonal antibody-based therapies. CD15 may serve as a prognostic marker for patients and there are high hopes for its use in the immunotherapeutic treatment of tumours. CD15s is a sialyl derivative of CD15 that possesses its own unique characteristics. Its soluble form may act as a competitive inhibitor of the interaction of cancer cells with epithelial cells and thus disallow migration through the vessels. However, the prognostic relevance of CD15 and CD15s expression is very complex. This review presents a comprehensive description of the role of CD15 and CD15s in cancer development and metastasis and overviews its significance for clinical applications.

show abstract

Circulating CD15 ⁺ LOX‐1 ⁺ PMN‐MDSCs are a potential biomarker for the early diagnosis of non‐small‐cell lung cancer

Cited by 5 publications

References 41 publications

CD15 and CD15s in The Anticancer Therapy

CD15 and CD15s in The Anticancer Therapy

Functional Flow Cytometry to Predict PD‐L1 Conformational Changes

Prognostic and Therapeutic Role of CD15 and CD15s in Cancer

Contact Info

Product

Resources

About

Circulating CD15 + LOX‐1 + PMN‐MDSCs are a potential biomarker for the early diagnosis of non‐small‐cell lung cancer

Cited by 5 publications

References 41 publications

CD15 and CD15s in The Anticancer Therapy

CD15 and CD15s in The Anticancer Therapy

Functional Flow Cytometry to Predict PD‐L1 Conformational Changes

Prognostic and Therapeutic Role of CD15 and CD15s in Cancer

Contact Info

Product

Resources

About

Circulating CD15 ⁺ LOX‐1 ⁺ PMN‐MDSCs are a potential biomarker for the early diagnosis of non‐small‐cell lung cancer